// App-Quantinova.ai

: Dupilumab efficacy in children with uncontrolled, moderate-to-severe asthma with and without an allergic phenotype

Researchers

Presenter

  • Nikolaos Papadopoulos

Principal Investigators

  • Stanley J. Szefler

  • Leonard B. Bacharier

  • Jorge F. Maspero

  • Christian Domingo

  • Nadia Daizadeh

  • David J. Lederer

  • Megan Hardin

  • Juby A. Jacob-Nara

  • Yamo Deniz

  • Rebecca Gall

  • Benjamin Ortiz

  • Michel Djandji

  • Paul Rowe

Medical Centers

  • University of Colorado School of Medicine, Aurora, CO, United States

  • Fundacion GADOR, Buenos Aires, Argentina

  • Corporació Sanitària Parc Taulí, Sabadell, Autonomous University of Barcelona, Barcelona, Spain

  • Monroe Carell Jr Children’s Hospital at Vanderbilt University Medical Center, Nashville, TN, United States of America

  • Biogen, Cambridge, MA, United States of America

  • Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States.

  • Sanofi US, Bridgewater, United States of America

  • Royal Manchester Children's Hospital, Manchester, United Kingdom

Locations

  • United States

  • Spain

  • United Kingdom

  • Argentina

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Asthma

Biomarkers

  • N/A

Drug/Treatment

  • Dupilumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • NCT02948959

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved